- U.S. Study MapU.S. Study Map overview
- Updates
- LearnWhat is a clinical study? Which is right for me? Learn about these and other questions in this section
- About
STRONG SCD
The STRONG SCD study is evaluating different dose levels of an oral investigational drug designed to lessen SCD complications, including pain crises.
30 US sites, 1 Lebanon site
16 to 70 years
SS, SC, Sβ0 thal, Sβ+ thal
Phase 2
SCTaware
This is a study for parents of infants with Sickle Cell Trait (SCT) identified by newborn screening who are referred and present for in-person SCT education at the Institution.
1 US site
18 to 65 years
AS (sickle cell trait)
Phase 1 / Phase 2
Sickle Cell and Bone Health
To determine whether having sickle cell trait (SCT) is a risk factor bone thinning at an earlier age and to understand why individuals with sickle cell disease (SCD) have thinner bones than healthy individuals do.
1 US site
18 to 45 years
SCD and SCT
N/A
February 17, 2021
Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation.
February 17, 2021
The Bill and Melinda Gates Foundation and Novartis are collaborating to discover and develop a one-step, one-time gene therapy treatment to cure sickle cell disease, STAT News reports.
February 8, 2021
Results of a longitudinal prospective case-control study found rates of retinal thinning were higher among individuals with sickle cell retinopathy compared with individuals without the condition, and thinning rates increased as participants aged, and stages of retinopathy progressed.
Sending updates featuring new studies and other relevant information about emerging sickle cell treatment options.